Dear Editor Of Journal of Oncology Research,  
We could like to submit the enclosed manuscript entitled “Postoperative UFT-/Tegafur-based Chemotherapy versus Postoperative Radiotherapy for early-stage non-small cell lung cancer：A Systematic Review and Network Meta-analysis”, which we wish to be considered for publication in “Journal of Oncology Research”. No conflict of interest exists in the submission of this manuscript, and manuscript is approved by all authors for publication. I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part.  
This systematic review and meta-analysis was reported in accordance with the Preferred Items for Systematic Reviews and Meta-analysis (PRISMA) Statement and was registered at  
International Prospective Register of Systematic Reviews (number CRD42018095979).

Most clinicians think that postoperative UFT/Tegafur-based adjuvant chemotherapy is better than postoperative radiotherapy, but there is no direct evidence. Moreover, new studies have found that postoperative radiotherapy may also improve survival rates in early non-small cell lung cancer patients. Given no report of direct comparison between UFT/Tegafur based postoperative adjuvant chemotherapy and radiotherapy in treatment of early-stage non-small cell lung cancer, we performed this systematic review and network meta-analysis. Our results showed that UFT/Tegarfur based adjuvant chemotherapy could significantly improve the overall survival rate of patients [HR=0.69 (0.59-0.80) p=0.000] compared with postoperative adjuvant radiotherapy, but it also changed with different stages and radiotherapy methods, especially different radiotherapy interventions. Therefore, postoperative UFT/Tegarfur-based chemotherapy isn’t always superior to postoperative radiotherapy, which allows us to weigh the options of different methods. We believe this manuscript may be of particular interest to the readers of Journal of Oncology Research.  
We deeply appreciate your consideration of our manuscript, and we look forward to receiving  
comments from the reviewers. If you have any queries, please don’t hesitate to contact me at the address below.  
Sincerely yours,  
Shuaifei Ji, Pro.  
Air Force Medical University, Xi’an, China. E-mail: 1135260399@qq.com; Tel:13720538722.